|Bid||74.79 x 800|
|Ask||74.87 x 800|
|Day's Range||73.01 - 76.91|
|52 Week Range||31.86 - 100.77|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||101.91|
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 22 abstracts, including three oral presentations, were accepted at the 2021 American Academy of Neurology (AAN) virtual annual meeting being held from April 17 – 22. The abstracts are available on the AAN website at https://index.mirasmart.com/AAN2021/.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biohaven Pharmaceutical's first-quarter pre-announcement for sales of migraine treatment Nurtec ODT crushed Wall Street's expectations Wednesday. BHVN stock surged on the news.